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Abstract
Background: Antecedent hypertension is associated with poor outcome in patients with ST-elevation myocardial
infarction (STEMI). Whether differences in myocardial salvage, infarct size and microvascular injury contribute to the
adverse outcome is unknown. We investigated the association between antecedent hypertension and cardiovascular
magnetic resonance (CMR) parameters of myocardial salvage and damage in a multicenter CMR substudy of
the AIDA-STEMI trial (Abciximab Intracoronary versus intravenously Drug Application in ST-elevation myocardial infarction).
Methods: We analyzed 792 consecutive STEMI patients reperfused within 12 h after symptom onset. Patients underwent
CMR imaging for assessment of myocardial salvage, infarct size and microvascular obstruction within 10 days
after infarction. Major adverse cardiac events (MACE) were recorded at 12-month follow-up.
Results: Antecedent hypertension was present in 540 patients (68 %) and was associated with a significantly
increased baseline risk profile (advanced age, higher body mass index, higher incidence of diabetes, hypercholesterolemia,
previous angioplasty and multivessel disease, p< 0.001 for all). MACE were more frequent in patients with hypertension as
compared to patients without hypertension (45 [8 %] vs. 8 [3 %], p < 0.01). Antecedent hypertension remained
an independent predictor of MACE after multivariate adjustment (hazard ratio 3.42 [confidence interval 1.45–8.08],
p < 0.01). There was, however, no significant difference in the area at risk, infarct size, myocardial salvage index, extent
of microvascular obstruction, and left ventricular ejection fraction between the groups (all p > 0.05).
Conclusion: Despite a higher rate of MACE in contemporary reperfused STEMI patients with antecedent hypertension,
there was no difference in reperfusion efficacy, infarct size and reperfusion injury as visualized by CMR.
Trial registration: NCT00712101.
Keywords: Hypertension, ST-elevation myocardial infarction, Cardiovascular magnetic resonance, Major adverse
cardiac events
Background
Arterial hypertension (HTN) is a major cardiovascular
risk factor affecting approximately 30–45 % of the gen-
eral population [1, 2]. HTN is not only associated with
an increased incidence of other risk factors, but also dir-
ectly contributes to the development and progression of
atherosclerotic disease [3]. Accordingly, patients with
myocardial infarction (MI) and a history of HTN are
known to be older and to have a higher rate of comor-
bidities and more extensive atherosclerotic disease than
patients with MI but no HTN [4]. Several studies dem-
onstrated that patients with MI and antecedent HTN
are at increased risk for adverse cardiovascular events,
such as heart failure, recurrent MI or death [4–11].
However, whether differences in myocardial salvage, in-
farct size or microvascular injury contribute to the ad-
verse outcome in contemporary reperfused MI patients
is unknown. Cardiovascular magnetic resonance (CMR)
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is the reference technique for the determination of these
infarct characteristics [12], which are known to be
strongly correlated with clinical prognosis in patients
with ST-elevation MI (STEMI) reperfused by primary
percutaneous coronary intervention (PPCI) [13–16].
The aim of this study was therefore to assess the asso-
ciation of antecedent HTN with myocardial salvage and
damage determined by CMR as well as to evaluate its
prognostic significance on adverse clinical events in a
large multicenter cohort of consecutive patients treated
with PPCI for STEMI.
Methods
Study design and population
This was an analysis of data from the multicenter
CMR substudy of the AIDA STEMI trial (Abciximab
Intracoronary versus intravenously Drug Application in
ST-Elevation Myocardial Infarction; NCT00712101). The
rationale, design and main results of AIDA STEMI as well
as its CMR substudy have been reported elsewhere
[15, 17–20]. Briefly, AIDA STEMI randomized 2065
consecutive STEMI patients treated within 12 h after
symptom onset to either intracoronary or intravenous
abciximab bolus (0.25 mg/kg) during PPCI with a subse-
quent 12 h dose-adjusted intravenous infusion. The CMR
substudy enrolled 795 patients at 8 sites with proven ex-
pertise in CMR imaging, which was performed within
10 days after infarction. Importantly, there was no differ-
ence in CMR parameters of myocardial salvage and dam-
age between both treatment groups [20]. The presence of
antecedent arterial HTN was prospectively questioned
and hypertension was diagnosed if patients were on anti-
hypertensive treatment or had ≥3 systolic blood pressure
values >140 mmHg on at least two different days. Patients
were categorized as having antecedent HTN or not. Major
adverse cardiac events (MACE), defined as a composite of
all-cause death, nonfatal re-MI and new congestive heart
failure, were recorded at 12 months after STEMI. Detailed
endpoint definitions have been published previously [17].
The local ethics committees approved the study and all
patients gave a written informed consent.
Cardiovascular magnetic resonance
Patients were examined at rest in the supine position on
1.5 or 3.0 Tesla scanners at day 1 to 10 after STEMI. Stan-
dardized imaging sequences were used as described previ-
ously [17, 20, 21]. Blinded readers performed image
analysis at the CMR core laboratory (University of Leipzig
- Heart Center, Leipzig, Germany). Commercially available
software was used for post-processing (cmr42, Circle Car-
diovascular Imaging Inc., Calgary, Alberta, Canada). The
core laboratory has proven excellent reproducibility and
low inter- as well as intra-observer variability in patients
with acute STEMI [22]. Measurements of the area-at-risk,
infarct size, and microvascular obstruction were expressed
as the percentage of left ventricular (LV) volume (%LV).
Myocardial salvage index was determined from area at
risk and infarct size as previously described [13]. As de-
scribed previously [20], LV function was available for 792
patients. Late gadolinium enhancement (LGE) for the de-
termination of infarct size and microvascular obstruction
was available in 774 patients. T2-weighted imaging for the
assessment of the area-at-risk was available for 695 pa-
tients. The prevalence of incomplete CMR scans was not
significantly different between patients with or without
antecedent HTN.
Statistical analysis
Since most of the continuous variables were non-normally
distributed, all continuous data were expressed as median
with interquartile range for reasons of uniformity. Cat-
egorical data were depicted as counts and percentage.
Distribution of data was tested using the Shapiro-Wilk
test. Testing for differences between groups was per-
formed with Mann–Whitney-U test or Kruskal-Wallis
test for continuous variables and x2-test for categorical
variables. To identify predictors of infarct size, micro-
vascular obstruction, myocardial salvage index, and left
ventricular ejection fraction, multiple linear regression
analysis was performed. Outcome functions were
assessed using Kaplan-Meier graphs with log-rank com-
parison between groups. In addition, univariate and
multivariate Cox regression analysis was performed to
identify predictors for time to MACE. Multivariate ana-
lysis was performed using variables with a p < 0.05 in
univariate analysis. All variables listed in Table 1 were
assessed in univariate analysis (except the TIMI risk
score). Tests were two-tailed, and a probability value of
<0.05 was considered statistically significant. All ana-




Between July 2008 and April 2011 795 STEMI patients
were enrolled in the CMR substudy of the AIDA STEMI
trial. Information on antecedent HTN was available in
792 (99.6 %) patients, representing the final study co-
hort. Characteristics of the overall cohort as well as
stratified by history of HTN are listed in Table 1. Ante-
cedent HTN was associated with more advanced age, a
higher body mass index, a higher prevalence of female
sex, diabetes mellitus, hypercholesterolemia (p < 0.001
respectively), multivessel disease (p < 0.01), and previous
myocardial infarction (p < 0.01), but a lower preva-
lence of current smoking (p < 0.001). HTN was also
associated with a higher systolic blood pressure on
admission (p < 0.001) and a trend for a higher diastolic
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Table 1 Baseline characteristics
All patients (n = 792) Hypertension (n = 540) No hypertension (n = 252) p value
Age, years 62 [51–71] 66 [55–73] 54 [48–63] <0.001
Male sex, n (%) 600 (76) 389 (72) 211 (84) <0.001
Body mass index, kg/m2 27 [25–30] 28 [25–31] 26 [24–29] <0.001
Cardiovascular risk factors
Current smoking, n (%) 339/724 (43) 194/482 (36) 145/242 (58) <0.001
Diabetes mellitus, n (%) 160/789 (20) 142/539 (26) 18/250 (7) <0.001
Hypercholesterolemia, n (%) 303/784 (38) 250/536 (46) 53/250 (21) <0.001
Family history for CAD, n (%) 268/611 (34) 177/407 (33) 91/204 (36) 0.79
Systolic blood pressure, mmHg 130 [117–147] 135 [119–150] 126 [114–140] <0.001
Diastolic blood pressure, mmHg 80 [70–88] 80 [70–90] 80 [70–85] 0.07
Heart rate, beats/min 76 [67–87] 76 [68–88] 76 [65–85] 0.23
Time from symptom onset to PCI hospital admission, min 180 [109–310] 183 [110–311] 166 [104–306] 0.23
Door-to-balloon time, min 30 [22–42] 30 [23–42] 29 [20–42] 0.56
Previous infarction, n (%) 48/791 (6) 42/539 (8) 6/631 (2) <0.01
Previous PPCI, n (%) 67 (9) 61 (11) 6 (2) <0.001
Previous CABG, n (%) 11 (1) 11 (2) 0 (0) 0.02
Anterior infarction, n (%) 395/755 (50) 262/516 (49) 133/239 (53) 0.21
Killip-class on admission 0.52
1, n (%) 696 (88) 472 (87) 224 (89)
2, n (%) 59 (7) 42 (8) 17 (7)
3, n (%) 20 (3) 16 (3) 4 (2)
4, n (%) 17 (2) 10 (2) 7 (3)
Number of diseased vessels <0.01
1, n (%) 419 (53) 261 (48) 158 (63)
2, n (%) 225 (28) 165 (31) 60 (24)
3, n (%) 148 (19) 114 (21) 34 (14)
Infarct related artery 0.59
Left anterior descending, n (%) 344 (43) 240 (44) 104 (41)
Right coronary artery, n (%) 344 (43) 226 (42) 118 (47)
Left circumflex, n (%) 97 (12) 68 (13) 29 (12)
Left main, n (%) 5 (1) 4 (1) 1 (0)
Bypass graft, n (%) 2 (0) 2 (0) 0 (0)
TIMI risk score 3 [2–5] 4 [2–5] 2 [2–4] <0.001
TIMI-flow before PPCI 0.64
TIMI-flow 0, n (%) 444 (56) 298 (55) 146 (58)
TIMI-flow 1, n (%) 103 (13) 73 (14) 30 (12)
TIMI-flow 2, n (%) 128 (16) 92 (17) 36 (14)
TIMI-flow 3, n (%) 117 (15) 77 (14) 40 (16)
TIMI-flow after PPCI 0.38
TIMI-flow 0, n (%) 12 (2) 9 (2) 3 (1)
TIMI-flow 1, n (%) 19 (2) 14 (3) 5 (2)
TIMI-flow 2, n (%) 61 (8) 47 (9) 14 (6)
TIMI-flow 3, n (%) 699 (88) 469 (87) 230 (91)
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blood pressure (p = 0.07) with no significant difference in
heart rate (p = 0.23). Pre- and post-PPCI TIMI-flow were
equal in both groups (p = 0.64 and p = 0.38, respectively).
Antecedent hypertension and clinical outcome
During the follow-up period of 12 months, 53 patients
(7 %) experienced MACE. Of these 22 (3 %) died. Pa-
tients with antecedent HTN were at higher risk for
MACE (45 [8 %] versus 8 [3 %], p < 0.01; hazard ratio:
2.70 [1.27–5.72], p = 0.01) and mortality (20 [4 %] versus
2 [1 %], p = 0.02; hazard ratio: 4.83 [1.13–20.67], p = 0.03)
as compared to patients without antecedent HTN
(Table 2). Consequently, antecedent HTN showed a
significant association with MACE- and mortality-free
survival (p < 0.01 and p = 0.02, respectively, Fig. 1). In
multivariate Cox regression analysis, antecedent HTN
was independently associated with the occurrence of
MACE (Table 3). In a second Cox regression model
including established CMR prognosis markers (left ven-
tricular ejection fraction, infarct size, microvascular ob-
struction), antecedent HTN was also independently
associated with MACE after 12 months (hazard ratio: 2.55
[1.20–5.43], p = 0.02). 339 (43 %) of patients had HTN at
the time of the acute event (defined as systolic blood pres-
sure of ≥140 mmHg and/or diastolic blood pressure of ≥
90 mmHg). In contrast with antecedent HTN, HTN at the
time of the acute event was not significantly associated
with the rate of MACE (log-rank p = 0.18).
Antecedent hypertension and cardiovascular magnetic
resonance findings
The median time between the index event and CMR
scan was 3 [2–4] days. CMR findings and their rela-
tion with antecedent HTN are shown in Table 4. Pa-
tients with antecedent HTN had a similar extent of
the area at risk (p = 0.18), infarct size (p = 0.74),
microvascular obstruction (p = 0.93), and a compar-
able myocardial salvage index (0.20). There was also
no significant difference in left ventricular ejection
fraction between groups (p = 0.47). Antecedent HTN
was not predictive for infarct size, microvascular obstruc-
tion, myocardial salvage index or left ventricular ejection
fraction at linear regression analyses (all p > 0.05). The
power of this study to exclude a difference in infarct size
or LV ejection fraction of 3 % between groups is 94.9 and
98.5 %, respectively.
Discussion
This is the first study evaluating the impact of ante-
cedent HTN on CMR parameters of myocardial salvage
as well as myocardial and microvascular damage in pa-
tients undergoing PPCI for acute STEMI. There are
two main findings: (1) antecedent HTN was independ-
ently associated with a higher rate of MACE and mor-
tality at 12-month follow-up; (2) however, there were
no differences in CMR-determined myocardial salvage,
infarct size or extent of microvascular obstruction be-
tween patients with or without antecedent HTN. To-
gether, these findings highlight the importance of a
history of HTN as risk factor of adverse outcome in
contemporary reperfused STEMI patients, which is
however not attributed to differences in PPCI efficacy
(myocardial salvage), extent of myocardial necrosis or
microvascular injury as visualized by CMR.
Antecedent hypertension, baseline risk profile and clinical
outcome
As a consequence of its well established role as a major
cardiovascular risk factor [1], antecedent HTN is a
Table 1 Baseline characteristics (Continued)
Stent implanted, n (%) 774 (98) 527 (98) 247 (98) 0.60
Thrombectomy, n (%) 190 (24) 124 (23) 66 (26) 0.32
Concomitant medications
Aspirin, n (%) 790 (100) 538 (100) 252 (100) 1.0
ß-blockers, n (%) 757 (96) 519 (96) 238 (94) 0.19
ACE-I/ARB, n (%) 751 (95) 515 (95) 236 (94) 0.21
Statin, n (%) 749 (95) 508 (94) 241 (96) 0.47
Aldosterone antagonist, n (%) 80 (10) 55 (12) 25 (10) 0.34
Data are given as median plus interquartile range or number and percentage
Abbreviations: CAD coronary artery disease, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, TIMI thrombolysis in myocardial
infarction, ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker








MACE, n (%) 53 (7) 45 (8) 8 (3) <0.01
Death, n (%) 22 (3) 20 (4) 2 (1) 0.02
Re-infarction,
n (%)
21 (3) 16 (3) 5 (2) 0.42
Heart failure
event, n (%)
25 (3) 21 (4) 4 (2) 0.08
Data are given as number and percentage
Abbreviations: MACE major adverse cardiac events
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frequent finding in MI patients. In our analysis, history of
HTN was present in 68 % of STEMI patients. These results
fit well with recent prospective STEMI registry studies
which reported a prevalence between 60 and 70 % [23, 24].
Antecedent HTN has been acknowledged as significant risk
factor for adverse outcome in survivors of acute MI for
many years [4–6]. For instance, Thune et al. found that
antecedent HTN at the time of MI was strongly associated
with an increased risk of future heart failure, stroke, cardio-
vascular death and a composite endpoint consisting of
death, myocardial infarction, heart failure, stroke, or cardiac
arrest in more than 14.000 patients included in the VALI-
ANT trial (Valsartan in Myocardial Infarction Trial) [4].
Nevertheless, over the last years, reperfusion strategies and
pharmacological interventions were significantly refined
and consequently improved the outcome of patients
presenting with acute MI [25]. These advances might
have modified the relationship between HTN and the
clinical course after STEMI [26]. Indeed, in a meta-
analysis performed by Chen et al. the strength of the
association between antecedent HTN and poor clinical
outcome has decreased over time [11]. However, ante-
cedent HTN was still associated with increased MACE
and mortality rates at 12-month follow-up in our study.
This was also observed after adjustment for confound-
ing variables. Therefore, our findings highlight that
even in the contemporary era of PPCI the simple infor-
mation of HTN history can be used to identify patients
at risk for adverse prognosis post-STEMI. This high
risk group might also benefit from more intensified
medical treatment strategies including aggressive anti-
hypertensive treatment. Contrary to the information on
antecedent HTN, HTN at the time of the acute event
was not related with MACE in our study. Consequently,
antecedent HTN seems of greater importance as com-
pared with HTN at the time of STEMI.
It is well established that MI patients with a history of
HTN show a distinctive baseline risk profile, irrespective
Fig. 1 Kaplan-Meier curves for the occurrence of major adverse cardiac events and death according to antecedent hypertension
Table 3 Predictors of MACE in uni- and multivariate Cox regression analysis
Univariate Multivariate
HR (95 % CI) p value HR (95 % CI) p value
Age, >median 2.49 [1.38–4.47] <0.01 - -
Gender, 1 female 1.95 [1.12–3.40] 0.02 - -
Smoking status, 1 yes 0.46 [0.24–0.87] 0.02 - -
Diabetes mellitus, 1 yes 1.91 [1.07–3.41] 0.03 - -
Hypertension, 1 yes 2.70 [1.27–5.72] 0.01 3.42 [1.45–8.08] <0.01
Heart rate, >median 1.96 [1.12–3.43] 0.02 - -
Killip-class, I-IV 1.90 [1.46–2.48] <0.001 1.91 [1.40–2.60] <0.001
Vessel Disease, I-III 1.34 [1.01–1.78] 0.04 - -
Uni- and multivariate Cox regression analysis for the prediction of MACE at 12 months after infarction. Only significant variables in univariate analysis are reported
Abbreviations: MACE major adverse cardiac events, HR hazard ratio, CI confidence interval
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of STEMI or non-STEMI presentation. Studies consist-
ently observed that hypertensive patients with MI were
older, more often female, had a higher body mass index,
and higher rates of other cardiovascular risk factors in-
cluding diabetes or hypercholesterolemia [6–10]. Our
data confirm these previous findings and it is likely that
these factors might at least partly explain the higher risk
of hard clinical events of hypertensive STEMI patients.
Further observations from our and other studies are the
higher incidence of a previous cardiac disease and the
greater extent of coronary artery disease [4, 7, 9, 10].
Since both have been proved to be associated with ad-
verse clinical outcome in STEMI patients [27], these fac-
tors might also contribute to the increased risk of
infarction patients with antecedent HTN. Recent studies
could also disclose that diffuse myocardial fibrosis, mea-
sured by T1 mapping, is increased in patients with
hypertension and previous infarction [28].
Antecedent hypertension and infarct characteristics
It has been speculated that coronary occlusion in pa-
tients with pre-existing HTN might be associated with
more extensive myocardial damage, greater myocardial
dysfunction, and consequently adverse clinical outcome
[11, 26]. Contrary, one might argue that a higher dia-
stolic pressure could enhance coronary perfusion and
collateral circulation with subsequently improved effi-
cacy of reperfusion and limited expansion of myocardial
necrosis. Studies investigating the impact of antecedent
HTN on myocardial damage are very limited so far [29].
In particular, there is no study answering these questions
by using the current reference standard technique,
which is CMR [12]. CMR not only enables exact infarct
sizing but also detailed tissue characterization of the
jeopardized and infarcted myocardium [12]. These add-
itional assessed parameters, primarily microvascular
obstruction, but also myocardial salvage index provide
strong prognostic information that is incremental to
clinical, biomarker, electrocardiographic, and angio-
graphic risk markers [15, 30]. To the best of our know-
ledge, the study by De Luca et al. [29]. is the first and
only study that evaluated the impact of HTN on infarct
size in 830 STEMI patients undergoing PPCI. The au-
thors found that HTN was not associated with larger
infarcts as determined by scintigraphy at 1 month after
infarction. Nevertheless, some important limitations of
this study have to be mentioned. The authors used a
scintigraphic technique to assess infarct size, which is
less accurate compared to CMR, especially for the de-
tection of subendocardial infarcts [31]. Secondly, De
Luca et al. were also not able to assess the association
of antecedent HTN with myocardial salvage and micro-
vascular dysfunction. Our study therefore complements
and extends the previous literature by showing for the
first time that the adverse outcome of reperfused
STEMI patients with antecedent HTN is not associated
with differences in reperfusion success or more pro-
nounced myocardial injury.
Limitations
Our study has some important limitations. Based on the
in- and exclusion criteria of this multicenter clinical trial
as well as the treatment of patients in specialized high-
volume centers, our results might not be generalizable
to all STEMI populations. Although AIDA STEMI was
designed as all-comers trial to represent a “real-world”
STEMI population [18, 20], further confirmation of our
findings in other studies would be important. It is, how-
ever, important to note that the power of our study to
exclude a 3 % difference in infarct size or LV ejection
fraction between groups was approximately 95 %. Infor-
mation on HTN was based on patient history and data
on the duration of HTN as well as patients adherence to
medication and effectiveness of HTN treatment, which
could have prognostic implications as well, was not
available. Nevertheless, our study shows that the simple
assessment of antecedent HTN by anamnesis or during
hospitalization has strong prognostic implications in
STEMI patients treated with PPCI. Forty-eight patients
(6 %) had a previous myocardial infarction. Chronic in-
farcts were not included in infarct size measurements
and thus the “true volume” of the infarcted myocardium
Table 4 Cardiovascular magnetic resonance findings
All patients (n = 792) Hypertension (n = 540) No hypertension (n = 252) p value
Area at risk, % LV 35 [25–48] 34 [25–47] 37 [26–49] 0.18
Infarct size, % LV 16.7 [8.5–24.9] 16.9 [8.8–24.8] 16.6 [8.3–25.0] 0.74
Presence of microvascular obstruction, n (%) 400 (51) 274 (51) 126 (50) 0.85
Extent of microvascular obstruction, % LV 0 [0–1.8] 0 [0.0–1.6] 0 [0.0–2.0] 0.93
Myocardial salvage index, % area at risk 51 [33–69] 50 [33–67] 54 [32–72] 0.20
LV ejection fraction, % 50 [43–58] 50 [43–58] 51 [44–58] 0.47
LV myocardial mass, g 132 [109–156] 134 [111–158] 131 [109–155] 0.38
Data are given as median plus interquartile range or number and percentage
Abbreviations: CMR cardiovascular magnetic resonance, LV left ventricular
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is not represented in the reported values. On the other
hand, omitting those patients from statistical analysis
did not significantly change the results.
Conclusion
This study found higher rates of MACE and mortality in
contemporary reperfused STEMI patients with ante-
cedent HTN despite no difference in reperfusion success
and extent of myocardial and microvascular damage as
determined by CMR.
Abbreviations
AIDA-STEMI: Abciximab Intracoronary versus intravenously Drug Application
in ST-elevation myocardial infarction; CMR: Cardiovascular magnetic
resonance; HTN: Arterial hypertension; LV: Left ventricular; MACE: Major adverse
cardiac events; MI: Myocardial infarction; PPCI: Primary percutaneous coronary
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